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Abstract  
Background: Arachidonic acid (AA) is the major polyunsaturated fatty acid (PUFA) substrate 
for potent eicosanoid signaling to modulate inflammation and thrombosis, and controlled in 
part by tissue abundance. Fatty acid desaturase 1 (FADS1) catalyzes synthesis of omega-6 AA 
and omega-3 eicosapentaenoic acid (EPA). The rs66698963 polymorphism, a 22-bp insertion-
deletion (Indel) 137-bp downstream of a sterol regulatory element in FADS2 intron 1, mediates 
expression of FADS1 in vitro, as well exerting positive selection in several human populations. 
The associations between polymorphism rs66698963 and plasma PUFA, as well as disease 
phenotypes are unclear. 
Objective: This study aimed to evaluate the relationship between rs66698963 genotypes and 
plasma PUFA levels, and blood lipid profiles. 
Design: Plasma fatty acids were measured from a single sample obtained at baseline in 1,504 
healthy Chinese adults aged between 35–59 years using gas chromatography. Blood lipids were 
measured at baseline and a second time after 18 months follow up. The rs66698963 genotype 
was determined using agarose gel electrophoresis. Linear regression and logistic regression 
analyses were performed to assess the association between genotype and plasma PUFA and 
blood lipids. 
Results: A shift from precursors linoleic acid and alpha-linolenic acid to product AA and EPA, 
respectively, was observed consistent with FADS1 activity increasing in the order of genotypes 
D/D to I/D to I/I. For I/I compared with D/D carriers, plasma levels of omega-6 AA and the 
ratio of AA to omega-3 EPA plus docosahexaenoic acid (DHA) were 57% and 32% higher 
respectively. Carriers of the deletion (D) allele of rs66698963 trended to higher triglycerides 
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(TG) (β(SE)=0.018(0.009), P=0.05) and lower high-density lipoprotein cholesterol (HDL-C) 
(β(SE)= -0.008(0.004), P=0.02) than carriers of the insertion (I) allele.  
Conclusions: The rs66698963 genotype controls AA and AA to EPA+DHA levels reflecting 
basal risk for inflammatory and related chronic disease phenotypes, and is correlated with risk 
of dyslipidemia. 
Keywords: dyslipidemia, gene polymorphism, fatty acid desaturases, insertion–deletion, long 
chain polyunsaturated fatty acids  
5 
 
Introduction 
Arachidonic acid (20:4n-6, AA) is the major long chain polyunsaturated fatty acid 
(LCPUFA) precursor for more than 100 signaling molecules modulating inflammation (1), 
thrombosis (2), and blood pressure (3), amid a host of other specialized functions. Eicosanoid 
production is controlled at the level of substrate concentration, where phospholipase catalyzed 
membranes release free AA to be rapidly oxidized in the first steps of eicosanoid synthesis (5). 
Nutritional regulation of eicosanoid synthesis has long been tied to intake of the omega-3 
LCPUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which, as available, 
populate membrane phospholipids and are also released by phospholipases. EPA and DHA 
compete for eicosanoid synthetic enzymes with AA, effectively lowering the production of AA-
derived 2-series eicosanoids and yielding EPA-derived 3-series eicosanoids as well as the more 
recently described docosanoids, some of which signal for the resolution of inflammation (6).  
The delta-5 desaturase (D5D) and delta-6 desaturase (D6D), encoded by FADS1 and 
FADS2 genes, respectively, are the key enzymes in the biosynthesis of long chain 
polyunsaturated fatty acids (LCPUFA), including AA, EPA, and DHA (1). Earlier studies 
have consistently found numerous SNPs in FADS1 and FADS2 genes, such as rs174537, 
rs174550, rs174553, rs174570, rs174575, and rs1535 to be associated with blood PUFA 
levels and lipid profiles (2-11). Moreover, omega-3 LCPUFA modulate peroxisome 
proliferator activated receptors (PPARs) which promote reverse cholesterol transport (12). 
Fish oil, rich in EPA and DHA, potently reduces blood triglycerides (TG), as well as total 
cholesterol (TC) to a minor degree, and increases high-density lipoprotein cholesterol (HDL-
C) (13). Dyslipidemia is one of the independent risk factors for cardiovascular diseases (14). 
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In China, the prevalence of high TC, high TG, and low HDL-C has all increased by about 
10%, from 2002 to 2012 (15).  
 Insertion/deletion(s) (Indels) represent the second most frequent human polymorphisms 
after SNPs (16). The rs66698963 polymorphism is a 22-bp insertion-deletion variant located 
137 bp downstream from a sterol regulatory element in FADS2 intron 1 identified in 
lymphoblasts from the International Hapmap project (17). Our previous data showed that the 
insertion (I) allele was associated with higher FADS1 expression and higher erythrocyte AA 
levels in a small study (18). Examination of the 1000 Genomes data showed that this locus 
exerts positive selection related to ancestral diet: populations with low intake of animal foods, 
where AA is found, have predominantly the insertion-insertion (I/I) genotype that supports 
higher expression of FADS1, the AA synthase (18). Taken together these in vitro, in vivo, and 
in silico data are strongly suggesting that the rs66698963 is a causal locus modulating 
circulating AA levels via endogenous synthesis. They also strong suggest that circulating 
omega-3 PUFA should follow a similar pattern, but no relationship was found for the omega-3 
PUFA so far (18). Here we aimed to use a prospective population-based study to further 
establish the relationship between rs66698963 genotype and PUFA levels, and explore the 
association with blood lipid profiles. 
Subjects and methods  
Study population 
Samples were collected from a cohort referred to as Study on Major Chronic Disease Risk 
Assessment System and Related Technology Developing and Application (19). The study was 
conducted from April 2010 to December 2012, involving more than 7,000 subjects from four 
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project sites including two rural and two urban areas: Shunyi of Beijing (rural), Tongxiang of 
Zhejiang (rural), Haidian of Beijing (urban), and Jiaxing of Zhejiang (urban). Eligible 
participants had to live in the corresponding area for more than one year, had no plan to move 
within one year, and had no serious diseases of heart, lung, liver, and kidney. Among the four 
sites, only Shunyi was included in the current study. A total of 2,008 subjects aged between 35 
and 59 years were recruited in Shunyi. All participants were interviewed in-person at baseline 
to collect demographic data, disease history, personal medical conditions, cigarette smoking, 
drinking, health education and related information. Fasting venous blood was obtained for 
measurements of plasma fatty acids, and biochemical tests including TC, HDL-C, TG, glucose, 
and others. Low-density lipoprotein cholesterol (LDL-C) was calculated according to the 
Friedewald formula: LDL-C=TC-(HDL-C)-TG/2.2. For the individuals with TG≥4.5 mmol/L, 
LDL-C was defined as missing (20). Non-high-density lipoprotein cholesterol (nHDL-C) was 
calculated by formula: nHDL-C=TC-(HDL-C) (21). Plasma was separated at 1500g/min 
centrifugation for 15min. Whole blood and plasma were stored at -80°C until used. After about 
18 months, 1622 (81%) of the subjects were successfully interviewed again. The information 
on health, cigarette smoking, drinking, and blood lipid profiles including TC, HDL-C, and TG 
were obtained again. For the current study, individuals selected: (1) had no history of 
cardiovascular diseases, malignant neoplasm, or other serious disease; (2) had valid data of 
both plasma PUFA levels and FADS2 rs66698963 status. The final count was n=1,504 (75%) 
participants at baseline which were used in all analyses of genotype-plasma fatty acid status 
and genotype-blood lipid analysis. Among them, follow-up data was available from 1,206 
(80%) subjects. (Supplemental Figure 1). Follow-up analyses for genotype blood lipids only 
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are presented in Supplemental materials only. 
The study protocol was approved by the Institutional Review Board of Chinese Center for 
Disease Control and Prevention. All participants provided written informed consent. This study 
is registered at Chinese Clinical Trial Registry (Clinical Trial Registry number: ChiCTR-EOC-
17012759). 
Genotyping rs66698963 
Indel rs66698963 is located 137-bp downstream from a sterol regulatory element (SRE) 
(25). Genomic DNA was extracted from whole blood and used to amplify a 200 base pair 
fragment flanking the SRE of FADS2 intron 1 (GenBank Accession# NT_167190.1) by PCR. 
The following primer pairs were used: forward primer: 5’CAAAGCTGGTCACCACTGC3’, 
reverse primer: 5’TCAGGGAAAAGAGACGTGCT3’. The PCR was performed in a 10ul 
reaction, consisting of 35 ng genomic DNA, 2.5 pmol of each primer, and 5ul PCR mix 
(Lifefeng Biotechnology Co. Ltd, Shanghai, China). Thermal Cycling conditions were: initial 
denaturation at 94 °C for 10 min followed by 35 cycles of denaturation at 94 °C for 30 s, 
annealing at 59 °C for 30 s and extension at 72 °C for 30 s, with a final extension at 72 °C for 
10 min. The PCR products were run on 3% agarose gels until the bands were well separated. 
After staining with ethidium bromide (EB), DNA bands were visualized under UV. The 
concordance rate was greater than 98.7% based on 11% re-run samples (n = 158). Genotypes 
of samples were assigned as insertion/insertion (I/I), insertion/deletion (I/D), and 
deletion/deletion (D/D). Agarose gel image of rs66698963 polymorphism and genotype 
frequency in our study are shown in Supplemental Figure 2. 
Plasma total fatty acid measurement 
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Gas chromatography/flame ion detector (GC/FID) was used to measure plasma total fatty 
acids profiles from the fasting blood samples as previously described(22). Briefly, 100ul 
plasma and10 ug 1,2-dihenarachidoyl-sn-glycero-3-phosphocholine as internal standard was 
extracted with dichloromethane/methanol solution(22), and then converted to fatty acid 
methyl esters(FAMEs) with methanol and sulfuric acid(23). After methyl esterification, 
FAMEs were extracted with n-hexane and re-dissolved in isooctane. Analysis was performed 
by GC/FID (Agilent 6890 GC) equipped with a Supelco SP-2560 capillary column (100m x 
0.25mm inside diameter x 0.20um thickness). The plasma level of each fatty acid was 
expressed as weight percentage of total fatty acids. Samples were organized in 20 batches. 
Two quality control samples from a standard pool were inserted in each batch. The coefficient 
of variation (CVs) of QC ranged from 3.69% to 16.58%. 
Definition of hyperlipidemia and obesity 
According to the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in 
Adults (2007)(24), hyperlipidemia was defined as total cholesterol (TC≥5.18 mmol/L), and/or 
high-density lipoprotein cholesterol (HDL-C<1.04 mmol/L), and/or triglycerides (TG ≥1.70 
mmol/L), and/or with history of hyperlipidemia diseases in the past one year. Body mass index 
(BMI) was defined base on criteria in China: Underweight with BMI<18.5 kg/m2, normal 
weight with 18.5≤BMI<24 kg/m2, overweight with 24≤BMI<30 kg/m2, and obese with 
BMI≥30 kg/m2. Central obesity (WC) was defined as WC≥90 cm for men and ≥ 80 cm for 
women based on the International Diabetes Federation recommendations for Asians(25) 
Statistical analysis 
One degree of freedom Pearson Chi-squared test was employed to check whether the 
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Hardy Weinberg equilibrium (HWE) law holds in the total sample. The Kruskal-Wallis test 
on continuous variables and the Chi-squared test on categorical variables were used to 
examine the differences in basic characteristics between three genotype groups. Additive 
genetic model was used in the analysis. Genotypes I/I, I/D, and D/D (I for I-allele and D for 
D-allele) were coded as 0, 1, and 2, respectively, and were taken as a continuous variable in 
regression models. P-trend values for lipid profiles and LCPUFA from I/I to I/D to D/D were 
obtained from linear regression models. To control false positive error, p-trend were corrected 
by Bonferroni with alpha=0.0125(4 lipid profiles exploratory comparisons) and 
alpha=0.003(16 LCPUFA exploratory comparisons).  
Multiple linear regression models were applied to examine the associations of 
rs66698963 with plasma lipids at baseline. Prior to the multiple linear regressions, TC, TG, 
HDL-C, LDL-C, and nHDL-C were log10 transformed. Multivariable-adjusted odds ratios 
(ORs) and 95% confidence interval (CI) were obtained from logistic regression. 
Hypertriglyceridemia, hypercholesterolemia, or low-HDL-C was considered as case of 
dyslipidemia in our study. As the highest frequency genotype, I/I genotype was used as 
reference. To evaluate the association between rs66698963 with plasma lipids in the 18-
month follow-up, logistic regression was performed in the follow-up data of subjects with 
normal blood lipids at baseline. In the above linear regression and logistic models, several 
adjustment models were used: 1) model adjusted for age and sex (basic model); 2) model 
adjusted for sex, age, BMI, smoking, diabetes, hypertension, and farm working (full model); 
3) model adjusted for sex, age, BMI, smoking, diabetes, hypertension, farm working, and 
AA/(EPA+DHA) (exploration model). Confounders in analysis were selected by prior known 
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and potential risk factors for dyslipidemia. We also used Kruskal-Wallis test and chi-square 
test to evaluate the differences of the variants between dyslipidemia and non- dyslipidemia in 
this study. Those variants whose p<0.05 were considered as confounders and were included 
in the models. Farm working was one of variables that p<0.05 and was suspected to be 
associated with lipid profiles, so farm working should be considered as a confounder and 
controlled in our analysis.  
To explore the effect modification by plasma PUFA levels and some other factors on the 
association between rs66698963 and blood lipids, stratified analyses were conducted by 
sex(male, female), age(<median,≥median), obesity(yes, no), hypertension(yes, no), current 
smoking (yes or no, defined by at least once a week over one year), current alcohol drinking 
(yes or no, defined by at least once a week over one year), farm working (yes or no, defined 
by doing farm work over one year), physical activity (yes or no, defined by at least once a 
week over one year), and various plasma PUFA(low, high). It was noted that plasma PUFA 
were classified into low and high groups based on the median levels in healthy subjects 
without dyslipidemia at baseline. Interactions were assessed by entering the cross product of 
genotype and interest modifying factor in the multiple regression models. P-interaction values 
were calculated by Wald test in linear regression models, and log-likelihood ratio test in 
logistic models.    
All analyses were conducted with the SAS software (version 9.3). All P-values are two-
sided. A P-value less than 0.05 was considered as statistically significant. 
Results 
Baseline characteristics 
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Participant characteristics (n=1,504) at baseline are shown in Table 1. In our sampling 
(n=1,504), D/D genotype was 11.84% (n = 178), I/D 42.35% (n = 637), and I/I 45.81% 
(n = 689); the observed allele frequency was D=33% and I=67%, and the genotypes are in 
HW equilibrium (P = 0.10). No obvious differences were found among genotypes for age, 
education, diabetes, current alcohol drinking, and physical activity. The D/D group had 
significantly lower HDL-C, and marginally significant (p = 0.08) higher TG than the I/I 
group. 
 
Plasma PUFA levels among the three genotype at baseline 
The D/D participants had significantly higher plasma 18:2n-6, 20:2n-6, 20:3n-6, 18:3n-3, 
and lower 18:3n-6, 20:4n-6, 22:4n-6, 22:5n-6, 20:5n-3, 22:5n-3, 22:6n-3, and 
AA/EPA+DHA, than those for I/I genotype (all Ptrend<0.0001) (Figure 1). The rs66698963 
D/D was negatively associated with the ratios of 18:3n-6/18:2n-6 and 20:4n-6/20:3n-6, which 
are often used as a proxy for the activity of D6D and D5D, respectively (Figure 1). 
Compared to D/D genotype, omega-6 AA levels and the AA/EPA + DHA ratio were 57% and 
32% increased respectively for individuals of I/I genotype. 
 
Association between genotype and lipid profiles at baseline 
 At baseline, rs66698963 D/D was significantly associated with higher TG 
(β(SE)=0.018(0.009), P=0.05) and lower HDL-C (β(SE)= -0.008(0.004), P=0.02) in full 
model (Table 2, model 2). To examine whether the balance of AA and EPA+DHA may 
mediate the effect of rs66698963 on lipid profiles, we further adjusted the models for the 
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AA/EPA+DHA ratio and the associations were not significant (Table 2, model 3). Compared 
to I/I genotype, odds ratios (ORs) of D/D genotype were 1.10 (95%CI: 0.73, 1.67) and 
1.47(95%CI: 1.03, 2.08) for hypertriglyceridemia and low-HDL-C dyslipidemia respectively 
in full model (Table 3).  
 
Stratified analyses 
We investigated the combined effects of rs66698963 and some potential modifiers of 
dyslipidemia on the lipid profiles. Significant interactions were observed for rs66698963 
genotypes with hypertension and physical activity (Supplemental Table 1). The association 
between D/D genotype and low-HDL-C dyslipidemia tended to be stronger in subjects 
without physical activity (OR=1.79; 95%CI: 1.24, 2.6; Pinteraction=0.01), or in subjects without 
hypertension (OR=2.09; 95%CI: 1.31, 3.36; Pinteraction=0.002) (Figure 2, Supplemental Table 
2). The interactions between rs66698963 and plasma PUFA were also analyzed. The 
significant associations between rs66698963 D/D and higher TG were restricted to 
individuals with lower plasma 18:2n-6, DHA, and EPA+DHA (Pinteraction=0.04, 0.02, and 
0.004, respectively) (Figure 3, Supplemental Table 3). However, the significant association 
between D/D genotype and lower HDL-C was only observed when 20:3n-6 and 20:5n-
3/18:3n-3 levels were higher (Pinteraction=0.008 and 0.008 respectively), or when EPA+DHA 
level was lower (Pinteraction= 0.004) (Figure 3, Supplemental Table 3). Lower TC was 
associated with rs66698963 D/D genotype only when the 20:5n-3/18:3n-3 ratio was higher 
(P=0.0003, Pinteraction= 0.0005) (Supplemental Table 3). No interaction was found between 
rs66698963 and plant-derived PUFA (18:2n-6 or 18:3n-3) on downstream PUFA such as AA, 
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EPA, and DHA (Supplemental Table 4). 
 
Associations between genotype and lipid profiles in 18-month follow-up 
For the individuals with normal HDL-C (n=1099) at baseline, we observed an 
association between rs66698963 D/D genotype and decreased HDL-C level at 18-month 
follow up (Supplemental Table 5). However, the significant association was limited to the 
individuals without physical activity (OR =2.18; 95%CI: 1.24, 3.82) (Supplemental Table 
6), and individuals without hypertension (OR=2.77; 95% CI: 1.33, 5.78) (Supplemental 
Table 6).   
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Discussion 
The D/D genotype was associated with lowest AA, DHA, EPA, and AA/EPA+DHA ratio; 
D/D genotype was also associated with higher TG and lower HDL-C levels. EPA+DHA 
levels modified the associations of rs66698963 genotype with plasma TG and HDL-C. 
Additionally, 18:2n-6 or DHA alone modified the association of genotype with plasma TG; 
while physical activity and hypertension modified the association of genotype with HDL-C.   
The rs66698963 Indel polymorphism was strongly associated with plasma omega-6 
PUFA. The relationship followed expectations from a precursor-product relationship with 
respect to FADS1 (Figure 1B, 1E). For omega-6 PUFA, the precursors (18:2 and 20:3) 
accumulate in the progression from I/I to I/D to D/D; and the products (20:4, 22:4, and 
22:5) increase from D/D to I/D to I/I (Figure 1B). Higher 20:4n6/20:3n6 ratio suggests 
greater D5D desaturase activity for I/I compared with D/D genotype, consistent with our 
previous studies (17, 18).  
For the first time we also observed a significant precursor-product relationship in 
omega-3 PUFA synthesis, following the pathway 18:320:522:522:6 (Figure 1B, 1C). 
The magnitudes of the percentage decreases in 20:4n-6 and 20:5n-3 were similar from I/I to 
D/D consistent with the hypothesis that FADS1 expression and activity is regulating PUFA 
concentrations along both pathways similarly, as expected from biochemical competition.  
Importantly, the ratio of AA to EPA+DHA increased by 32% from D/D to I/I (Figure 
1D) due to a greater increase in AA than EPA and DHA. AA is precursor for mostly 
inflammatory, clotting signaling eicosanoids. EPA and DHA inhibit synthesis of those 
compounds and are precursors for resolving and other signaling molecules that oppose the 
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action of AA. Circulating omega-3 EPA and DHA are robustly associated with reduction of 
cardiovascular diseases (26). Sources of omega-3 LCPUFA, primarily seafood or marine oil 
supplements, are recommended for primary prevention of cardiovascular diseases, and for 
reduction of plasma triacylglycerol (13). Our data suggest that individuals with the D/D 
genotype may be especially vulnerable to dietary omega-3 insufficiency compared to 
individuals of I/I genotype. Importantly, controversy over the effects of omega-3 and 
cardiovascular disease(27-29) may be related to this genetic factor, considering that I/I 
individuals will have a greater mean basal EPA and DHA level, and therefore be less well 
differentiated from placebo groups than a supplemented group. 
The rs66698963 genotype frequency in our study population was similar to that in India, 
but different from a small sampling of an urban US population (18). Differences in ethnic, 
geographical, and dietary intake related evolution between Chinese and Americans are likely 
to explain the different frequency. Rural inland regions including those in China and India 
tend to rely more on plants and have low intakes of PUFA rich foods (30) compared to diets 
of the ancestors of Americans.Populations subsisting for many generations on plant-based 
diets depend on greater endogenous LCPUFA biosynthesis, favoring the I/I genotype that is 
adaptive in evolution (18). Our data strongly support the hypothesis that those of I/I genotype 
consuming a conventional diet would particularly benefit from balanced dietary PUFA. 
 The Japanese HapMap population has two linkage disequilibrium (LD) blocks in the 
FADS gene cluster whereas the Chinese (and Europeans) populations have only 1 LD block 
(17, 31). Minor allele homozygotes (D/D) present in about one quarter of the Japanese 
population had significantly lower expression of FADS1 than the I/I homozygotes (17) , and 
17 
 
AA was lower in individuals of D/D genotype (18). Previous characterizations of LD were 
based on SNPs while Indels and other variations in this region have been mis-called or 
omitted. LD estimates for Indels must be approached with caution unless measured by 
definitive methods such as in the present work. 
The rs66698963 Indel is 137-bp downstream of an SRE, approximately the length of a 
nucleosome (146-bp) and very likely modifying regulatory protein binding at the SRE. 
FADS2 SNPs associated with PUFA and blood lipid profiles (rs174570, rs174575, rs1535) 
may be tagging the function of rs66698963 Indel polymorphism (32). For example, the 
rs174570 T allele, 5,400-bp upstream of rs66698963, was associated with reduced LCPUFA 
in the Greenlandic Inuit population (33). The rs174570 derived “T” and ancestral “C” allele 
tag the deletion and insertion alleles of the 22-bp rs66698963 Indel, respectively. Further, 
rs174570 “T” allele frequency is 0.99 in Greenlandic Inuit and 0.34 in CHB (33), the Indel 
rs66698963 D allele frequency (0.33) in the present study is similar to that in CHB. The 
rs174570 ancestral “C” allele exhibited strong LD with the insertion allele of rs66698963, 
which is adaptive and showed positive selection signals in South Asians (nSL = −3.77, 
P = 0.00048) and East Asians (iHS = −2.41, P = 0.010; nSL = −2.41, P = 0.012) (18). 
Combined with previous work, our results provide solid evidence indicating that FADS2 
rs66698963, is a causal variant influencing PUFA and through them, blood lipid levels. 
Future studies focused on the association of classical SNP with Indel rs66698963 in specific 
populations would enable high throughput SNP analyses to serve as proxies for the Indel, 
which is currently measured by Sanger sequencing. 
The D/D genotype had 4.8% lower HDL-C and 7.5% higher TG than I/I genotype, in the 
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direction of increased dyslipidemia risk. EPA+DHA supplementation is a well-accepted 
treatment for hypertriglyceridemia. Our data also show concordance of increased EPA+DHA 
and lower TG. GWAS and genetic studies show that polymorphisms related to reductions in 
circulating EPA and DHA or increases in AA are associated with dyslipidemia (34). Several 
potential mechanisms link rs66698963 and blood lipids: (1) Lower omega-3 LCPUFA due to 
the D/D genotype may result in decreased activation of PPARs, which subsequently decreases 
the expression HDL-C component genes(21), including apo -lipoproteins (Apo) A-I, A-II, C-
III, and lipoprotein lipase (4, 35), and results in low-HDL-C; (2) omega-3 PUFA regulate the 
activity of nuclear receptors, reducing TG synthesis and decreasing very-low-density 
lipoprotein (VLDL) secretion (36). Moreover, our data showed significant positive 
associations of AA with TG, and negative association of AA with HDL-C (data not shown). 
AA/EPA+DHA may mediate the association between rs66698963 and lipid profiles. This 
hypothesis is supported by the abolishment of rs66698963-lipid association after adjustment 
for AA/EPA+DHA.  
FADS gene variants may interact with dietary omega-3 or omega-6 on lipid traits (20, 
21). The association between rs66698963 D/D genotype and higher TG was stronger when 
18:2n-6, DHA, and EPA+DHA levels were low. A striking association was also observed 
between rs66698963 D/D genotype and lower HDL-C when EPA+DHA level was low.The 
results are consistent with FADS1-rs174550 genotype association with lower HDL-C when 
18:2n-6 and 18:3n-3 were low (4). Higher EPA+DHA intake lowers TG by down-regulating 
lipogenic enzymes, enhancing intra hepatic degradation of Apo-lipoprotein B (Apo-B) and 
reducing activity of lipolytic enzymes (37). The effect of rs66698963 polymorphism on 
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circulating lipid profiles is likely to depend on dietary PUFA intake. 
This is the first study to examine the association between the Indel rs66698963 
polymorphism and disease biomarkers. The main strength of our study is that all outcomes 
are measured rather than estimated indirectly. Several limitations should be considered. Anti-
hyperlipidemia medication usage was not available, though according to Chinese National 
Nutrition and Health Survey in 2010-2013, the awareness rates (8.3%), treatment rates 
(7.0%), and detection rates (26.2%) are very low in rural areas of China(15). 
In conclusion, the present study shows that the rs66698963 Indel was strongly associated 
with circulating LCPUFA levels. The D/D genotype was associated with higher TG and lower 
HDL-C, modifiable by plasma levels of 18:2n-6, DHA, EPA+DHA, and physical activity. 
Together with previous evidence for positive selection for this specific Indel polymorphism, 
these findings suggest that this locus is pivotal for the relationship between diet and 
endogenous LCPUFA levels.   
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Table1. Population characteristics according to three genotypes of the Indel polymorphism at baseline 
Characteristics1 I/I(n=689) I/D(n=637) D/D(n=178) P2 P3 for trend 
Sex    0.002  
male 228(33.09) 187(29.36) 77(43.26)   
female 461(66.91)) 450(70.64) 101(56.74)   
Age(years) 49(45-54) 49(44-54) 48(43-53) 0.36  
BMI(kg/m2) 26.0(23.5-28.6) 25.86(23.7-28.5) 25.79(23.3-28.5) 0.99  
WC(cm) 85.2(77.8-93.2) 84.5(78.1-91.7) 86.0(78.2-94.1) 0.58  
Education    0.09  
illiteracy 25(3.63) 11(1.73) 2(1.12)   
Primary School 67(9.72) 81(12.72) 26(14.61)   
Middle School 451(65.46) 393(61.70) 115(64.61)   
High School 139(20.17) 142(22.29) 32(17.98)   
College 7(1.02) 10(1.57) 3(1.69)   
Current smoking 153(22.21) 129(20.25) 41(23.03) 0.59  
Current alcohol drinking 167(24.24) 156(24.49) 58(32.58) 0.06  
Obesity 95(13.79) 90(14.13) 28(15.73) 0.75  
Diabetes 12(1.74) 10(1.57) 6(3.37) 0.28  
Hypertension 301(43.69) 314(49.29) 77(43.26) 0.09  
Farm working 351(50.94) 305(47.72) 91(51.12) 0.46  
Physical activity 91(13.21) 81(12.72) 21(11.80) 0.88  
Lipid profiles      
Total Cholesterol, mmol/l 5.18(4.66-5.84) 5.18(4.58-5.72) 5.04(4.37-5.76) 0.14 0.60 
Triglyceride, mmol/l 1.07(0.75-1.58) 1.17(0.77-1.70) 1.15(0.75-1.63) 0.08 0.25 
HDL Cholesterol, mmol/l 1.45(1.26-1.70) 1.41(1.22-1.67) 1.38(1.17-1.61) 0.01* 0.02 
LDL cholesterol (mmol/l) 1.35(1.02-1.71) 1.37(1.04-1.72) 1.29(0.99-1.75) 0.84 1 
Abbreviation: D/D, homozygous for the deletion allele; I/D: heterozygous for the deletion allele; I/I, homozygous for the insertion allele; BMI, Body 
Mass index; WC, Waist Circumference 
1Continuous variables were expressed as median (interquartile) and categorical variables were expressed as frequency (percentage among I/I, I/D and D/D 
groups). 
2 Overall p values were calculated from Kruskal-Wallis test for continuous variables and χ2-test for categorical variables. * D/D vs I/I, P<0.05 
3P for trend values were obtained from linear regression using the additive model (increasing copy of FADS2-rs66698963 D-allele), and were adjusted by 
Bonferroni correction for lipid profiles. 
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Table2. Associations of FADS2 rs66698963 with blood lipids at baseline1 
Blood lipids  β(SE) P value  
TC     
Model 1  -0.004(0.003) 0.13  
Model 2  -0.004(0.003) 0.11  
Model 3  -0.004(0.003) 0.16  
TG 
 
   
Model 1  0.020(0.009) 0.04  
Model 2  0.018(0.009) 0.05  
Model 3  -0.015(0.009) 0.11  
HDL-C     
Model 1  -0.009(0.004) 0.02  
Model 2  -0.008(0.004) 0.02  
Model 3  0.0005(0.004) 0.9  
LDL-C     
Model 1  -0.001(0.007) 0.83  
Model 2  -0.002(0.006) 0.73  
Model 3  -0.005(0.007) 0.41  
nHDL-C     
Model 1  -0.002(0.004) 0.56  
Model 2  -0.003(0.004) 0.42  
Model 3  -0.005(0.004) 0.19  
25 
 
LDL-C/HDL-C     
Model 1  0.007(0009) 0.45  
Model 2  0.006(0.008) 0.50  
Model 3  -0.005(0.009) 0.54  
HDL-C/TG     
Model 1  -0.30(0.012) 0.016  
Model 2  -0.026(0.011) 0.02  
Model 3  0.016(0.012) 0.18  
1TC, TG, HDL-C, LDL-C, nHDL-C, LDL-C/HDL-C, and HDL-C/TG were log10-transformed 
before analyses.  β(SE) were obtained from multiple linear regression in additive model and 
represented changes in blood lipids for increasing number of D-alleles. 
 
Model 1: basic model adjusting for age and sex   
Model 2: full model adjusting for sex, age, BMI, smoking, diabetes, hypertension, and farm working. 
Model 3: model adjusting for sex, age, BMI, smoking, diabetes, hypertension, farm working, and 
AA/ EPA+DHA 
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Table3 The association of FADS2 rs66698963 and risk of dyslipidemia at baseline. 
 
genotype N  
(case/total) 
OR(95%CI)1 
(basic model2) 
OR(95%CI)1 
(full model3) 
TC I/I 348/689 1 1 
 
I/D 322/637 1.006（0.81,1.25） 0.98（0.79,1.23） 
 D/D 81/178 0.87（0.62,1.21） 0.87（0.62,1.22） 
TG I/I 144/689 1 1 
 
I/D 162/637 1.33（1.03,1.72） 1.33（1.02,1.75） 
 
D/D 41/178 1.11（0.74,1.65） 1.10（0.73,1.67） 
HDL-C I/I 291/689 1 1 
 
I/D 316/637 1.38（1.11,1.72） 1.41（1.12,1.77） 
 D/D 95/178 1.48（1.06,2.06） 1.47（1.03,2.08） 
Case outcomes were defined as hypercholesterolemia (TC ≥  5.18 mmol/l), and/or 
hypertriglyceridemia (TG ≥ 1.70 mmol/l), and/or low high-density lipoprotein cholesterol (HDL-
C < 1.04 mmol/l). 
1The odds ratio (OR) of hyper-TC, hyper-TG, and lower -HDL-C were obtained from logistic 
regression.  
2Basic model: adjusted for age and sex;  
3Full model: adjusted for sex, age, BMI, smoking, diabetes, hypertension, and farm working. 
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Figures with Figure Legends 
Figure 1: The association between rs66698963 and plasma fatty acids at baseline.  
Percent changes relative to the D/D were calculayed for each fatty acids. (A) omega-6 PUFA (B) 
LCPUFA pathway (C) omega-3 PUFA (D) the ratio of AA to EPA+DHA, and (E) the ratio of 
product to precursor which reflected D6D, D5D, and aggregate desaturase activity in omega-6 
PUFA pathway and omega-3PUFA pathway. Kruskal-Wallis was used to test the difference PUFA 
level among three genotype groups,* D/D vs I/I, P<0.05;**D/D or I/D vs I/I, P<0.05. P trend 
values were expressed as the linear association of plasma PUFA level and genotype from I/I to I/D 
to D/D and were obtained from simple linear regression. P trend values were adjusted by 
Bonferroni correction. All p trend are significant(p<0.001).  
Figure 2: Association of FADS2-rs66698963 and risk of dyslipidemia by potential modifiers at 
baseline.  
Stratification analysis was conducted in (A-C) physical activity and (D-F) hypertension. The odds 
ratios (ORs) of hypercholesterolemia, hypertriglyceridemia, and lower-HDL-C were obtained 
from logistic regression. ORs were adjusted for sex, age, BMI, smoking, diabetes, hypertension, 
and farm working. * represents P<0.05 in D/D compared with the I/I genotype (referent category) 
Figure 3: Interactions of FADS2- rs66698963 and plasma PUFA on blood lipids at baseline. 
Plasma fatty acids were classified into high vs low levels based on the median levels in subjects 
without dyslipidemia. Linear regression was conducted in (A-C) 18:2n6, (D-F) DHA, and (G-I) 
EPA plus DHA. P values for additive model per each group were indicated as P-low and P-high. P 
for interaction values were adjusted for sex, age, BMI, smoking, diabetes, hypertension, and farm 
working using an additive model. Data were expressed as geometric mean. 
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